Long-acting inhaled therapies and pulmonary rehabilitation are effective in stable COPD
- Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Dong, Yaa-Hui; Lin, Hsien-Ho; Shau, Wen-Yi; Wu, Yun-Chun; Chang, Chia-Hsuin; Lai, Mei-Shu // Thorax;Jan2013, Vol. 68 Issue 1, p48
Background: The active-treatment comparative safety information for all inhaled medications in patients with chronic obstructive pulmonary disease (COPD) is limited. We aimed to compare the risk of overall and cardiovascular death for inhaled medications in patients with COPD. Methods: Through...
- Corticosteroids plus long-acting beta-agonists reduce exacerbations more than long-acting Î²-agonists alone in COPD. McDonald, Christine // ACP Journal Club;Mar/Apr2008, Vol. 148 Issue 2, p23
The article focuses on 10 randomized controlled trials (RCTs) investigating how does inhaled corticosteroids (ICSs) combined with long-acting beta-agonists (LABAs) compare with LABAs alone in patients with stable chronic obstructive pulmonary disease (COPD). Trials found out that combined ICSs...
- Responsividade do teste do degrau de seis minutos a um programa de treinamento fÃsico em pacientes com DPOC. Marrara, Kamilla Tays; Marino, Diego Marmorato; Jamami, Maurício; de Oliveira Junior, Antônio Delfino; Pires Di Lorenzo, Valéria Amorim Pires // Jornal Brasileiro de Pneumologia;sep/oct2012, Vol. 38 Issue 5, p579
To evaluate the responsiveness of the six-minute step test (6MST) to an aerobic physical training program (PTP) and to determine the efficacy of the PTP regarding spirometric variables during the 6MST, as well as physical performance, sensation of dyspnea, and SpO2 during the 6MST and the...
- Optical Feedback Training of Inhalation with AutohalerÂ® and TurbuhalerÂ® in COPD Patients. Steier, J.; Trammer, T.; Cloes, R.M.; Petro, W. // Lung;2003, Vol. 181 Issue 4, p183
Assesses the effort to train patients with chronic obstructive pulmonary disease in the correct handling and optimal inhalation technique of the Autohaler and Turbuhaler devices. Assessment of handling by means of a checklist; Use of computer-based Inhalation Manager to evaluate optimal...
- Life-saving inhaler may damage the heart. Bown, William // New Scientist;11/24/90, Vol. 128 Issue 1744, p19
Announces that the government may revoke the license for the Berotec inhaler within weeks. National Asthma Campaign advice; Inhaler placed under active review; Heart damage that may be contacted to the use of the inhaler.
- One-Year Evaluation of the Safety and Efficacy of Ipratropium Bromide HFA and CFC Inhalation Aerosols in Patients with Chronic Obstructive Pulmonary Disease. Brazinsky, Shari A.; Lapidus, Robert J.; Weiss, Laurence A.; Ghafouri, Mo; Fagan, Nora M.; Witek, Theodore J. // Clinical Drug Investigation;2003, Vol. 23 Issue 3, p181
Introduction: Ipratropium bromide (IB) is an established and effective first-line maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). A new IB metered-dose inhaler (MDI) using hydrofluoroalkane 134a propellant (IB HFA) has been developed as an alternative to the...
- A Nail in the Coffin for Coughin'? Phillips, Barbara A. // Internal Medicine Alert;2/15/2009, Vol. 31 Issue 3, p17
The article reports on the results of a randomized, placebo-controlled trial of erythromycin in lessening obstructive lung diseases (COPD) exacerbations.
- Correction: Singing classes for chronic obstructive pulmonary disease: a randomized controlled trial. // BMC Pulmonary Medicine;2014, Vol. 14 Issue 1, p1
A correction to the article "Singing classes for chronic obstructive pulmonary disease: a randomized controlled trial" that was published in the November issue is presented.
- Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. Kai-Michael Beeh; Beier, Jutta; Donohue, James F. // Respiratory Research;Jun2012, Vol. 13 Issue 6, p1
Randomised, double-blind, controlled trials are considered the gold standard for evaluating a pharmacological agent, as they minimise any potential bias. However, it is not always possible to perform double-blind trials, particularly for medications delivered via specific devices, e.g. inhalers....